

North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - 2025-2033

<https://marketpublishers.com/r/N01B85F134D3EN.html>

Date: May 2025

Pages: 188

Price: US\$ 3,750.00 (Single User License)

ID: N01B85F134D3EN

Abstracts

Overview

The North America metabolic dysfunction-associated steatohepatitis (MASH) treatment market size reached US\$ 3.70 billion in 2024 and is expected to reach US\$ 17.15 billion by 2033, growing at a CAGR of 19.3% during the forecast period 2025-2033.

Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Nonalcoholic Steatohepatitis (NASH), is a disease caused by a build-up of fat in the liver, not caused by alcohol consumption. As a result of fat deposition, the liver becomes inflamed (hepatitis). The inflammation and liver damage from MASH can cause fibrosis and scarring, and can lead to cirrhosis, where the liver is scarred and significantly damaged, often permanently. The development of MASH is linked with underlying conditions such as metabolic syndrome, obesity, and type 2 diabetes.

The obesity rate is rising continuously in North America, with about 38 million people having diabetes, which is about 1 in every 10 people, creating a direct risk factor for NASH/MASH. Currently, there is only one FDA-approved drug for NASH/MASH, which is Rezdiffra (resmetirom), making these diseases an area of high unmet medical need, which drives company focus for new therapies.

For instance, on March 14, 2024, Madrigal Pharmaceuticals, Inc. cleared the U.S. Food and Drug Administration (FDA) accelerated approval for Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials.

Market Dynamics: Drivers & Restraints

The rising prevalence of underlying conditions is significantly driving the metabolic dysfunction-associated steatohepatitis (MASH) treatment market growth.

The rising prevalence of underlying conditions such as obesity, type 2 diabetes, and other metabolic syndromes contributes significantly to the development of liver diseases, particularly NASH and MASH, which are increasingly recognized as public health concerns in North America. For instance, according to the Centers for Disease Control and Prevention, the prevalence of obesity among adults was 40.3% during August 2021–August 2023. The prevalence was 39.2% in men and 41.3% in women.

Obesity is a major risk factor for both NASH and MASH. The obesity rate has surged over the past few decades in North America, especially in the United States, contributing directly to an increase in liver-related diseases. In obese individuals, excess fat accumulation in the liver (known as NAFLD, Non-Alcoholic Fatty Liver Disease) can progress to more severe stages such as NASH. About 20-30% of people with NAFLD will eventually develop NASH, increasing the demand for effective treatments.

Type 2 diabetes is another major risk factor for NASH/MASH. The prevalence of type 2 diabetes in North America is increasing at an alarming rate, with more than 38 million Americans having diabetes (about 1 in 10), and about 90% to 95% of them have type 2 diabetes. Type 2 diabetes leads to insulin resistance, a metabolic dysfunction that is strongly linked to fat accumulation in the liver (a hallmark of NASH/MASH). Additionally, the fatty liver associated with diabetes can exacerbate insulin resistance, creating a vicious cycle. The prevalence of underlying conditions leads to the high prevalence of MASH, which further accelerates the market for better treatment.

The growing prevalence of these underlying conditions has prompted pharmaceutical companies to accelerate the development of novel therapies for NASH/MASH. Currently, several treatments are in late-stage clinical trials, targeting different disease mechanisms such as fibrosis, liver inflammation, and insulin resistance. Drugs like Semaglutide, Survodutide, Pegzofermin, Lanifibranor, Denifanstat, and Efruxifermin are emerging as potential solutions to address the growing MASH prevalence.

Limited availability of approved drugs is hampering market growth

The limited availability of approved drugs is one of the major challenges hampering the

growth of the market. Despite growing awareness, increasing diagnosis, and rising demand for effective treatments, the market is constrained by the fact that only one drug is currently approved, which is Rezdiffra (resmetirom) for the treatment of NASH/MASH, and many promising drugs are still in clinical trials or facing regulatory hurdles. This has created a significant gap between the need for effective treatments and their availability, impacting patient care and limiting market growth.

The lack of approved drugs means that patients with NASH/MASH have limited therapeutic options, and the growth of the market is slower than it could be. With only one approved drug, healthcare providers may be limited in the treatment options they can offer. Another challenge contributing to the limited availability of drugs is the lack of long-term data on the efficacy and safety of existing and trialed drugs. Most of the NASH/MASH drugs currently being tested are still undergoing long-term clinical trials, and many do not have substantial data on how they affect the disease in the long run.

Segment Analysis

The North American metabolic dysfunction-associated steatohepatitis (MASH) treatment market is segmented based on stage, age group and gender.

Stage:

Stage 4 segment are expected to dominate the North America metabolic dysfunction-associated steatohepatitis (MASH) treatment market with the highest market share.

Cirrhosis (fibrosis stage 4), the liver exhibits extensive scarring that changes its shape. Despite this severe damage, the liver can still function and may have the capacity to repair some of the injuries. However, if excessive scarring occurs, the liver's ability to carry out its essential functions may be impaired. This stage represents a critical condition that requires continuous management to prevent further deterioration and related complications.

At this stage, the individuals diagnosed with cirrhosis are indicating severe liver damage and scarring. This group includes those with compensated cirrhosis, where the liver still functions adequately despite significant scarring, and decompensated cirrhosis, where the liver can no longer maintain its functions, leading to serious complications such as fluid accumulation (ascites), jaundice, or hepatic encephalopathy. This statistic highlights a major public health concern, as it points to a substantial population at risk for severe health complications and emphasizes the urgent need for effective

management and treatment strategies.

Competitive Landscape

Top companies in the North America metabolic dysfunction-associated steatohepatitis (MASH) treatment market include Madrigal Pharmaceuticals. And the emerging players includes Novo Nordisk A/S, Boehringer Ingelheim International GmbH, 89bio, Inc., Inventiva, Sagimet Biosciences, and Akero Therapeutics, Inc., among others

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.

Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.

Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.

Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.

Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.

Competitive Strategies: Analyze competitor strategies, market share, and emerging players.

Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.

Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.

Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.

Sustainability & Regulatory Impact: Focuses on eco-friendly practices and

evolving regulations in healthcare.

Post-market Surveillance: Uses post-market data to enhance product safety and access.

Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The North America metabolic dysfunction-associated steatohepatitis (MASH) treatment market report delivers a detailed analysis with 30 key tables, more than 22 visually impactful figures, and 188 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

Supply Chain: Distribution and Supply Chain Managers.

Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

Academic & Research: Academic Institutions.

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Stage
- 2.4. Snippet by Age Group
- 2.5. Snippet by Gender

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Prevalence of Underlying Conditions
 - 3.1.1.2. Rising Awareness on NASH/MASH
 - 3.1.1.3. XX
 - 3.1.2. Restraints
 - 3.1.2.1. Limited Availability of Approved Drugs
 - 3.1.2.2. Patient Compliance Issues
 - 3.1.2.3. XX
 - 3.1.3. Opportunity
 - 3.1.3.1. Emerging Therapeutic Developments
 - 3.1.3.2. Partnerships and Collaborations
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established Leaders with the Largest Marketing Brand
 - 4.1.3. Market Leaders with Established Products
- 4.2. Latest Developments and Breakthroughs

- 4.3. North America Regulatory and Reimbursement Landscape
- 4.4. Porter's Five Forces Analysis
- 4.5. Epidemiology Analysis
- 4.6. Pipeline Analysis
- 4.7. Supply Chain Analysis
- 4.8. Patent Analysis
- 4.9. SWOT Analysis
- 4.10. Unmet Needs and Gaps
- 4.11. Recommended Strategies for Market Entry and Expansion
- 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.13. Pricing Analysis and Price Dynamics

5. METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) TREATMENT MARKET, BY STAGE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
 - 5.1.2. Market Attractiveness Index, By Stage
- 5.2. Stage 4*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Stage 2-3
- 5.4. Stage 0-1

6. METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) TREATMENT MARKET, BY AGE GROUP

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 6.1.2. Market Attractiveness Index, By Age Group
- 6.2. Geriatrics*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Adults
- 6.4. Pediatrics

7. METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) TREATMENT MARKET, BY GENDER

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

7.1.2. Market Attractiveness Index, By Gender

7.2. Male*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Female

8. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

8.1. Competitive Overview and Key Market Players

8.2. Market Share Analysis and Positioning Matrix

8.3. Strategic Partnerships, Mergers & Acquisitions

8.4. Key Developments in Product Portfolios and Innovations

8.5. Company Benchmarking

9. COMPANY PROFILES

Key market Players

9.1. Madrigal Pharmaceuticals*

9.1.1. Company Overview

9.1.2. Product Portfolio

9.1.2.1. Product Description

9.1.2.2. Product Key Performance Indicators (KPIs)

9.1.2.3. Historic and Forecasted Product Sales

9.1.2.4. Product Sales Volume

9.1.3. Financial Overview

9.1.3.1. Company Revenue

9.1.3.2. Geographical Revenue Shares

9.1.3.3. Revenue Forecasts

9.1.4. Key Developments

9.1.4.1. Mergers & Acquisitions

9.1.4.2. Key Product Development Activities

9.1.4.3. Regulatory Approvals, etc.

9.1.5. SWOT Analysis

Emerging Companies

9.2. Novo Nordisk A/S

9.3. Boehringer Ingelheim International GmbH

9.4. 89bio, Inc.

- 9.5. Inventiva
 - 9.6. Sagimet Biosciences
 - 9.7. Akerio Therapeutics, Inc.
- LIST NOT EXHAUSTIVE

10. ASSUMPTION AND RESEARCH METHODOLOGY

- 10.1. Data Collection Methods
- 10.2. Data Triangulation
- 10.3. Forecasting Techniques
- 10.4. Data Verification and Validation

11. APPENDIX

- 11.1. About Us and Services
- 11.2. Contact Us

List Of Tables

LIST OF TABLES

Table 1 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Stage, 2025, 2029 & 2033 (US\$ Billion)

Table 2 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Age Group, 2025, 2029 & 2033 (US\$ Billion)

Table 3 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Gender, 2025, 2029 & 2033 (US\$ Billion)

Table 4 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Stage, 2025, 2029 & 2033 (US\$ Billion)

Table 5 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Stage, 2022-2033 (US\$ Billion)

Table 6 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Age Group, 2025, 2029 & 2033 (US\$ Billion)

Table 7 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Age Group, 2022-2033 (US\$ Billion)

Table 8 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Gender, 2025, 2029 & 2033 (US\$ Billion)

Table 9 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, By Gender, 2022-2033 (US\$ Billion)

Table 10 Madrigal Pharmaceuticals: Overview

Table 11 Madrigal Pharmaceuticals: Product Portfolio

Table 12 Madrigal Pharmaceuticals: Key Developments

Table 13 Novo Nordisk A/S: Overview

Table 14 Novo Nordisk A/S: Product Portfolio

Table 15 Novo Nordisk A/S: Key Developments

Table 16 Boehringer Ingelheim International GmbH: Overview

Table 17 Boehringer Ingelheim International GmbH: Product Portfolio

Table 18 Boehringer Ingelheim International GmbH: Key Developments

Table 19 89bio, Inc.: Overview

Table 20 89bio, Inc.: Product Portfolio

Table 21 89bio, Inc.: Key Developments

Table 22 Inventiva: Overview

Table 23 Inventiva: Product Portfolio

Table 24 Inventiva: Key Developments

Table 25 Sagimet Biosciences: Overview

Table 26 Sagimet Biosciences: Product Portfolio

Table 27 Sagimet Biosciences: Key Developments

Table 28 Akero Therapeutics, Inc.: Overview

Table 29 Akero Therapeutics, Inc.: Product Portfolio

Table 30 Akero Therapeutics, Inc.: Key Developments

List Of Figures

LIST OF FIGURES

Figure 1 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 2 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Stage, 2024 & 2033 (%)

Figure 3 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Age Group, 2024 & 2033 (%)

Figure 4 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Share, By Gender, 2024 & 2033 (%)

Figure 5 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Y-o-Y Growth, By Stage, 2023-2033 (%)

Figure 6 Stage 4 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 7 Stage 2-3 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 8 Stage 0-1 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 9 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Y-o-Y Growth, By Age Group, 2023-2033 (%)

Figure 10 Geriatrics Age Group in North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 11 Adults Age Group in North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 12 Pediatrics Age Group in North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 13 North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Y-o-Y Growth, By Gender, 2023-2033 (%)

Figure 14 Male Gender in North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 15 Female Gender in North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 16 Madrigal Pharmaceuticals: Financials

Figure 17 Novo Nordisk A/S: Financials

Figure 18 Boehringer Ingelheim International GmbH: Financials

Figure 19 89bio, Inc.: Financials

Figure 20 Inventiva: Financials

Figure 21 Sagimet Biosciences: Financials

Figure 22 Akero Therapeutics, Inc.: Financials

I would like to order

Product name: North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - 2025-2033

Product link: <https://marketpublishers.com/r/N01B85F134D3EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N01B85F134D3EN.html>